Artikel ; Online: Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention.
International journal of molecular sciences
2021 Band 22, Heft 19
Abstract: Crohn's disease (CD) is a chronic disorder characterized by full thickness patchy inflammation of the gastrointestinal tract. The pathogenesis is multifactorial and involves defective innate immune responses, microbiome alterations, and dysregulated ... ...
| Abstract | Crohn's disease (CD) is a chronic disorder characterized by full thickness patchy inflammation of the gastrointestinal tract. The pathogenesis is multifactorial and involves defective innate immune responses, microbiome alterations, and dysregulated activation of the acquired component of mucosal immunity. One of the molecular mediators that is involved at different levels in the initiation and progression of intestinal inflammation characteristic of CD is tumor necrosis factor (TNF). The present manuscript provides a comprehensive review focused on the potential role of TNF in the different phases of CD pathogenesis, particularly in light of its potential clinical implications. Currently available drugs blocking TNF are evaluated and discussed, specifically for open issues that still remain utilizing such therapy. TNF exerts a paramount role in the established phase of intestinal inflammation that characterizes CD patients, and anti-TNF biologics have definitely changed patient management, offering effective and safe options of treatment. Nonetheless, many patients still do not respond to anti-TNF therapy or experience unwanted side-effects. This could partially be due to the role that TNF plays in intestinal homeostasis that is particularly important during the early phase of the inflammatory process. In fact, emerging evidence supporting the dichotomous role of TNF and the identification of molecular markers will guide a more tailored and refined therapy for CD patients in the near future. |
|---|---|
| Mesh-Begriff(e) | Adalimumab/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; Certolizumab Pegol/therapeutic use ; Crohn Disease/etiology ; Crohn Disease/immunology ; Crohn Disease/therapy ; Humans ; Immunosuppressive Agents/therapeutic use ; Infliximab/therapeutic use ; Molecular Targeted Therapy/methods ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/immunology |
| Chemische Substanzen | Anti-Inflammatory Agents ; Immunosuppressive Agents ; TNF protein, human ; Tumor Necrosis Factor Inhibitors ; Tumor Necrosis Factor-alpha ; Infliximab (B72HH48FLU) ; Adalimumab (FYS6T7F842) ; Certolizumab Pegol (UMD07X179E) |
| Sprache | Englisch |
| Erscheinungsdatum | 2021-09-24 |
| Erscheinungsland | Switzerland |
| Dokumenttyp | Journal Article ; Review |
| ZDB-ID | 2019364-6 |
| ISSN | 1422-0067 ; 1422-0067 ; 1661-6596 |
| ISSN (online) | 1422-0067 |
| ISSN | 1422-0067 ; 1661-6596 |
| DOI | 10.3390/ijms221910273 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.